

ANNEXE 1

Advisory Committee members & additional experts

ADVISORY COMMITTEE MEMBER	ORGANISATION	TITLE
Dr Ripley Ballou	GlaxoSmithKline Biologicals	Vice President and Head, Global Vaccines US R&D Center
Dr Graeme Bilbe	Drugs for Neglected Diseases Initiative (DNDi)	Research & Development Director
Dr François Bompard	Drugs for Neglected Diseases Initiative (DNDi)	Director of Paediatric HIV/HCV Programmes
Dr Wanderley de Souza	Financiadora de Estudos e Projetos (FINEP)	Former President
Dr Emily Erbeling	National Institute of Allergy and Infectious Diseases, National Institutes of Health	Director, Division of Microbiology and Infectious Diseases
Professor Alan Fenwick	Imperial College London	Professor of Tropical Parasitology
Dr Arnaud Fontanet	Institut Pasteur	Head of the Emerging Diseases Epidemiology Unit
Dr Sue Kinn	UK Department for International Development (DFID)	Team Leader and Research Manager
Dr Line Matthiessen	European Commission (EC)	Head of Infectious Diseases and Public Health Unit, Directorate-General for Research and Innovation
Dr Carl Mendel	TB Alliance	Senior Vice President, Research and Development
Dr Firdausi Qadri	International Centre for Diarrhoeal Disease and Research (icddr,b)	Emeritus Scientist and Acting Senior Director, Infectious Diseases Division
Dr John Reeder	World Health Organization: Special Programme for Research and Training in Tropical Diseases (WHO/TDR)	Director
Professor Nelson Sewankambo	Makerere University College of Health Sciences	Principal (Head)
Dr Soumya Swaminathan	World Health Organization	Deputy Director-General for Programmes
Wendy Taylor	The Rockefeller Foundation	Fellow
Dr Tim Wells	Medicines for Malaria Venture (MMV)	Chief Scientific Officer

ADDITIONAL EXPERT	ORGANISATION	TITLE
Professor Simon Croft	London School of Hygiene and Tropical Medicine (LSHTM)	Professor of Parasitology, Faculty of Infectious and Tropical Diseases
Professor Janet Hemingway	Liverpool School of Tropical Medicine (LSTM)	Director; Chair in Insect Molecular Biology
Dr Stephanie James	Foundation for the National Institutes of Health	Director of Science
Dr Patrick Lammie	The Task Force for Global Health	Chief Scientist, Neglected Tropical Diseases Support Center (NTD-SC)
Professor Marshall Lightowlers	University of Melbourne	Melbourne Laureate Professor
Professor Rosanna Peeling	London School of Hygiene and Tropical Medicine (LSHTM)	Professor and Chair of Diagnostics Research, and Director of the International Diagnostics Centre (IDC)
Dr Sarah Rees	Innovative Vector Control Consortium (IVCC)	Public Health Portfolio Manager
Professor Thomas W. Scott	University of California, Davis	Distinguished Professor, Department of Entomology and Nematology
Dr Joaquim Segalés	Foundation for Research in Animal Health (Centre de Recerca en Sanitat Animal) (CReSA)	Director

ANNEXE 2

Survey respondents

- AbbVie
- Aeras
- Against Malaria Foundation
- Aidsfonds*
- American Leprosy Missions (ALM)
- amfAR, The Foundation for AIDS Research*
- Apopo
- Argentinian Ministry of Science, Technology and Productive Innovation (MINCYT)
- Argentinian National Council for Scientific and Technical Research (CONICET)
- Arisan Therapeutics
- Austrade
- Australian Commonwealth Scientific and Industrial Research Organisation (CSIRO)
- Australian Department of Foreign Affairs and Trade (DFAT)
- Australian Department of Industry, Innovation and Science (DIIS)
- Australian National Health and Medical Research Council (NHMRC)
- Australian Research Council (ARC)
- Austrian Leprosy Relief Association (ALRA)
- Barcelona Institute for Global Health (ISGlobal) including Clinic Foundation for Biomedical Research (FCRB), Barcelona Centre for International Health Research (CRESIB), and Centre for Research in Environmental Epidemiology (CREAL)
- BASF
- Bayer CropScience
- Baylor College of Medicine
- Becton, Dickinson and Company (BD)
- Belgian Ministry of Foreign Affairs, Foreign Trade and Development Cooperation (DGDC)
- Bernhard Nocht Institute for Tropical Medicine (BNI)
- Bill & Melinda Gates Foundation
- BioCryst Pharmaceuticals
- Biological E
- Biotechnology Industry Research Assistance Council (BIRAC)
- Brazilian Araucária Support Foundation for Scientific and Technological Development in the State of Paraná (FAPPR)
- Brazilian Development Bank (BNDES)
- Brazilian Innovation Agency (FINEP)
- Brazilian Ministry of Health: Department of Science and Technology (DECIT)
- Brazilian Research Support Foundation of the State of Bahia (FAPESB)
- Brazilian Research Support Foundation of the State of Minas Gerais (FAPEMIG)
- Brazilian Support Foundation for Research in the State of Alagoas (FAPEAL)
- Brazilian Support Foundation for Research in the State of Amapá (FAPEAP)
- Brazilian Support Foundation for Research in the State of São Paulo (FAPESP)
- Brazilian Support Foundation for the Development of Education, Science and Technology in the State of Mato Grosso do Sul (FUNDECT)
- Burnet Institute
- California Institute for Regenerative Medicine (CIRM)*
- Campbell Foundation*
- Canadian Foundation for AIDS Research (CANFAR)*
- Canadian Institutes of Health Research (CIHR)
- Cebu Leprosy and Tuberculosis Research Foundation (CLTRF)
- Centre for Research in Animal Health, Centre de Recerca en Sanitat Animal (CRESA)
- Cepheid
- Chiang Mai University
- Chilean National Commission for Scientific and Technological Research (CONICYT)
- Chilean National Fund for Scientific and Technological Development (FONDECYT)

* Denotes organisations where funding data was only received via the Resource Tracking for HIV Prevention Research and Development Working Group

- Coalition for Epidemic Preparedness Innovations (CEPI)
- Colombian Department for Science, Technology and Innovation (Colciencias)
- Cuban Center for Genetic Engineering and Biotechnology (CIGB)*
- Daiichi-Sankyo
- Damien Foundation (DFB)
- Danish Ministry of Foreign Affairs and the Danish International Development Agency (DANIDA)
- DesignMedix
- Drugs for Neglected Diseases *initiative* (DNDi)
- Dutch Ministry of Foreign Affairs - Directorate General of Development Cooperation (DGIS)
- effect:hope (The Leprosy Mission Canada)
- Egyptian Academy of Scientific Research and Technology (ASRT)
- Eisai
- Elton John AIDS Foundation*
- Emergent Biosolutions
- European & Developing Countries Clinical Trials Partnership (EDCTP)
- European Commission (Directorate-General for Research and Innovation)[#]
- European Vaccine Initiative (EVI)
- FAIRMED
- FHI 360
- Fontilles
- Foundation for Innovative New Diagnostics (FIND)
- French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
- French National Institute of Health and Medical Research (Inserm)
- French National Research Agency (ANR)
- French Research Institute for Development (IRD)
- Fund to Support Scientific Research (FWF)
- Fundació La Caixa
- Gavi, The Vaccine Alliance

- GeoVax
- German Federal Ministry for Economic Cooperation and Development (BMZ)
- German Federal Ministry of Education and Research (BMBF)
- German Federal Ministry of Health (BMG)
- German Leprosy and TB Relief Association (DAHW)
- German Research Foundation (DFG)
- GlaxoSmithKline (GSK)
- Global Affairs Canada
- Global Good
- Global Health Innovative Technology Fund (GHIT Fund)
- GSK Bio
- Hawaii Biotech
- Health Research Council of New Zealand (HRC)
- Hebron
- Hospital Vall d'Hebron
- Ibero-American Program of Science and Technology for Development (CYTED)
- Indian Council of Medical Research (ICMR)
- Indian Council of Scientific and Industrial Research (CSIR)
- Indian Department of Biotechnology, Ministry of Science and Technology (DBT)
- Indian Department of Health Research, Union Ministry of Health and Family Welfare
- Indian Department of Science and Technology (DST)
- Innovate UK[#]
- Innovative Medicines Initiative (IMI)[#]
- Innovative Vector Control Consortium (IVCC)
- Institut Pasteur
- Institute of Tropical Medicine Antwerp (ITM)
- Integral Molecular
- International AIDS Vaccine Initiative (IAVI)
- International Centre for Genetic Engineering and Biotechnology (ICGEB)
- International Partnership for Microbicides (IPM)*

* Denotes organisations where funding data was only received via the Resource Tracking for HIV Prevention Research and Development Working Group

[#] Denotes organisations where funding data was taken from publicly available sources

- International Union Against Tuberculosis and Lung Disease
- International Vaccine Institute (IVI)
- Irish Aid
- Italian Association Amici di Raoul Follerau (AIFO)
- Italian National Institute of Health (ISS)*
- James Cook University including the Australian Institute of Tropical Health and Medicine (AITHM)
- Japanese National Institute of Infectious Diseases (NIID)*
- Johnson & Johnson
- KNCV Tuberculosis Foundation
- Korean Institute of Tuberculosis
- Lediand Biosciences
- Lepra including Lepra India - Blue Peter Public Health & Research Centre (BPHRC)
- Leprosy Relief Canada (SLC)
- Leprosy Research Initiative (LRI)
- Life Assay
- Liverpool School of Tropical Medicine (LSTM)
- Mapp Biopharmaceutical
- Max Planck Institute for Infection Biology (MPIIB)
- Médecins Sans Frontières (MSF)
- Medicines Development
- Medicines for Malaria Venture (MMV)
- Medicor Foundation
- Melbourne Children's Campus
- Meningitis Research Foundation (MRF)
- Mérieux Foundation
- Mexican National Council of Science and Technology (CONACYT)
- Mexican National Institute of Public Health (INSP)
- Mologen
- MSD / Merck
- Mundo Sano Foundation
- Mymetics
- Netherlands Leprosy Relief (NLR)
- Novartis

- Otsuka
- PATH including the Malaria Vaccine Initiative (MVI)
- Pharmaceutical Laboratory of the State of Pernambuco (LAFEPE)
- Population Council
- Public Health Agency of Canada (PHAC)*
- Public Health England (PHE)
- Research Centre Borstel
- Research Council of Norway
- Royal Norwegian Ministry of Foreign Affairs and the Norwegian Agency for Development Cooperation (NORAD)
- Royal Society of New Zealand (RSNZ)
- Sabin Vaccine Institute
- San Raffaele Scientific Institute (IRCCS)*
- Sanofi
- Sasakawa Memorial Health Foundation (SMHF)
- Science Foundation Ireland (SFI)
- Serum Institute of India
- Sidaction*
- South Africa Medical Research Council (MRC)
- South African Department of Science and Technology (DST)
- Spanish Ministry of Foreign Affairs and Cooperation for Development (MAEC)
- Sumagen*
- Swiss Agency for Development and Cooperation (SDC)
- Swiss National Science Foundation (SNSF)
- Swiss State Secretariat for Education, Research and Innovation (SERI)
- Swiss Tropical & Public Health Institute (Swiss TPH)
- Synstar Japan
- Sysmex
- Takeda Pharmaceutical Company
- TB Alliance
- Thai Government Pharmaceutical Organisation (GPO)
- Thai Red Cross AIDS Research Center (TRC-ARC)*

* Denotes organisations where funding data was only received via the Resource Tracking for HIV Prevention Research and Development Working Group

- Thai National Science and Technology Development Agency (NSTDA)
- The Leprosy Mission International (TLM)
- The Peter Doherty Institute for Infection and Immunity
- The Wellcome Trust
- TuBerculosis Vaccine Initiative (TBVI)
- Turing Foundation
- UBS Optimus Foundation
- UK Department for International Development (DFID)
- UK Department of Health and Social Care (DHSC)
- UK Medical Research Council (MRC)
- Unitaid
- University Hospital of Bonn (UKB)
- University of Buea
- University of Georgia
- University of Nebraska Medical Center
- University of Pittsburgh
- US Agency for International Development (USAID)
- US Centers for Disease Control and Prevention (CDC)
- US Department of Defense (DOD) including Defense Advanced Research Projects Agency (DARPA), US Army Medical Research Institute of Infectious Diseases (USAMRIID), the US Naval Medical Research Center (NMRC), Defense Threat Reduction Agency (DTRA) and the Walter Reed Army Institute of Research (WRAIR)[#]
- US National Institutes of Health (NIH) including the US National Institute of Allergy and Infectious Disease (NIAID)[#]
- Vaccitech
- Vestergaard
- ViiV Healthcare
- Volkswagen Foundation
- World Bank
- World Health Organization: Special Programme for Research and Training in Tropical Diseases (WHO / TDR)

[#] Denotes organisations where funding data was taken from publicly available sources

ANNEXE 3

REFERENCES

1. World Health Organization (WHO). Global strategy and plan of action on public health, innovation and intellectual property: report by the Director-General [Internet]. 2018 Mar [cited 2018 Apr 18]. (Seventy-first World Health Assembly). Report No.: A71/13. Available from: http://apps.who.int/gb/ebwha/pdf_files/WHA71/A71_13-en.pdf
2. World Health Organization (WHO). Addressing the global shortage of, and access to, medicines and vaccines: report by the Director-General [Internet]. 2018 Mar. (Seventy-first World Health Assembly). Report No.: A71/12. Available from: http://apps.who.int/gb/ebwha/pdf_files/WHA71/A71_12-en.pdf
3. World Bank. Data: country and lending groups [Internet]. 2017 [cited 2018 Apr 12]. Available from: <https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups>
4. Vasconcellos AG, Fonseca B de PF e, Morel CM. Revisiting the concept of Innovative Developing Countries (IDCs) for its relevance to health innovation and neglected tropical diseases and for the prevention and control of epidemics. *PLoS Negl Trop Dis*. 2018 Jul 12;12(7):e0006469.
5. Institute for Health Metrics and Evaluation (IHME). Global Health Data Exchange (GHDx) [Internet]. GBD Results Tool. 2018 [cited 2018 Apr 11]. Available from: <http://www.healthdata.org/institute-health-metrics-and-evaluation>
6. WHO and IHME collaborate to improve health data globally [Internet]. 2018 [cited 2018 Nov 14]. Available from: <http://www.healthdata.org/news-release/who-and-ihme-collaborate-improve-health-data-globally>
7. GBD 2017 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* [Internet]. 2018 Nov 10 [cited 2018 Nov 14];392. Available from: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(18\)31891-9/fulltext#seccestitle70](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31891-9/fulltext#seccestitle70)
8. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. *N Engl J Med*. 2009;361:2209–20.
9. National Institutes of Health (NIH). NIH and partners launch HIV vaccine efficacy study [Internet]. 2017 [cited 2018 Sep 25]. Available from: <https://www.nih.gov/news-events/news-releases/nih-partners-launch-hiv-vaccine-efficacy-study>
10. National Institute of Allergy and Infectious Diseases (NIAID). First new HIV vaccine efficacy study in seven years has begun [Internet]. National Institutes of Health (NIH). 2016 [cited 2018 Jun 1]. Available from: <https://www.nih.gov/news-events/news-releases/first-new-hiv-vaccine-efficacy-study-seven-years-has-begun>
11. AVAC: Global Advocacy for HIV Prevention. HVTN 703/HPTN 081 (the AMP study) [Internet]. AVAC. 2016 [cited 2018 Jun 1]. Available from: <http://www.avac.org/trial/hvtn-703hptn-081-amp-study>
12. Vieillard V, Gharakhanian S, Lucar O, Katlama C, Launay O, Autran B, et al. Perspectives for immunotherapy: which applications might achieve an HIV functional cure? *Oncotarget*. 2016 Feb 29;7(25):38946–58.
13. Pantaleo G, Levy Y. Therapeutic vaccines and immunological intervention in HIV infection: a paradigm change. *Curr Opin HIV AIDS*. 2016 Nov 1;11(6):576–84.
14. Treatment Action Group. Pipeline report 2018: the research toward a cure and immune-based therapies pipeline [Internet]. 2018 [cited 2018 Sep 25]. Available from: http://pipelinereport.org/sites/default/files/pipeline_2018_cure_ibt_rj_web3.pdf
15. Drugs for Neglected Diseases initiative (DNDi). DNDi 2017 annual report [Internet]. 2017 [cited 2018 Sep 25]. Available from: <https://www.dndi.org/annualreport2017/>
16. Treatment Action Group. The HIV PrEP and microbicides pipeline [Internet]. 2018 [cited 2018 Sep 25]. Available from: <http://www.pipelinereport.org/2018/hiv-prep-and-microbicides-pipeline>
17. International Partnership for Microbicides (IPM). IPM's application for dapivirine vaginal ring for reducing HIV risk in women now under review by European Medicines Agency [Internet]. 2017 [cited 2018 Sep 18]. Available from: <http://www.ipmglobal.org/content/ipm%E2%80%99s-application-dapivirine-vaginal-ring-reducing-hiv-risk-women-now-under-review-european>
18. World Health Organization (WHO). WHO list of prequalified in vitro diagnostic products [Internet]. 2017 [cited 2018 Jun 1]. Available from: http://www.who.int/diagnostics_laboratory/evaluations/PQ_list/en/
19. World Health Organization (WHO). Novel POC tools for early infant diagnosis of HIV [Internet]. Department of HIV/AIDS; 2017 [cited 2018 Sep 25]. Available from: <http://apps.who.int/iris/bitstream/handle/10665/255857/WHO-HIV-2017.16-eng.pdf;jsessionid=39BC01C168F25FCC93C2FBC4B73C10C7?sequence=1>
20. Roser M, Ritchie H. Malaria [Internet]. Our world in data. 2018 [cited 2018 Oct 6]. Available from: <https://ourworldindata.org/malaria>

REFERENCES

21. World Health Organization (WHO). Malaria vaccine implementation programme (MVIP) [Internet]. [cited 2018 Sep 25]. Available from: http://www.who.int/immunization/sage/meetings/2018/april/2_WHO_MalariaMVIPupdate_SAGE_Apr2018.pdf?ua=1
22. Malaria Vaccine Funders Group. Malaria vaccine technology roadmap [Internet]. Malaria Vaccine Initiative. 2013 [cited 2018 Jun 1]. Available from: <http://www.malariavaccine.org/malaria-and-vaccines/malaria-vaccine-roadmap>
23. World Health Organization (WHO). WHO vaccine pipeline tracker [Internet]. WHO. 2018 [cited 2018 Oct 6]. Available from: http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
24. Medicines for Malaria Venture. Interactive R&D portfolio [Internet]. 2017 [cited 2018 Jun 1]. Available from: <http://www.mmv.org/research-development/interactive-rd-portfolio>
25. Medicines for Malaria Venture. Pyramax [Internet]. 2017 [cited 2018 Jun 1]. Available from: <http://www.mmv.org/about-us/achievements-challenges/achievements/pyramax>
26. GSK. GSK submits US regulatory application for single-dose tafenoquine for Plasmodium vivax malaria [Internet]. 2017 [cited 2018 Jun 1]. Available from: <http://www-origin.gsk.com/en-gb/media/press-releases/gsk-submits-us-regulatory-application-for-single-dose-tafenoquine-for-plasmodium-vivax-malaria/>
27. Medicines for Malaria Venture. Annual report 2017 [Internet]. 2017 [cited 2018 Sep 25]. Available from: https://www.mmv.org/sites/default/files/uploads/docs/publications/MMV_AnnualReport2017.pdf
28. PATH. From pipeline to product: malaria R&D funding needs into the next decade [Internet]. 2013 [cited 2016 Sep 16]. Available from: http://www.path.org/publications/files/MVI_pipeline_to_product_r-d_rpt.pdf
29. World Health Organization (WHO). False-negative RDT results and implications of new reports of *P. falciparum* histidine-rich protein 2/3 gene deletions [Internet]. 2017 Sep [cited 2018 May 29]. Report No.: WHO/HTM/GMP/2017.18. Available from: <http://www.who.int/malaria/publications/atoz/information-note-hrp2-based-rdt/en/>
30. World Health Organization (WHO). Malaria: progress of the active applications in the prequalification of IVDs assessment pipeline [Internet]. 2018 [cited 2018 Sep 25]. Available from: http://www.who.int/diagnostics_laboratory/180710_malaria.pdf?ua=1
31. PATH. PATH and Mologic advance a new diagnostic test to support malaria elimination [Internet]. 2018 [cited 2018 Sep 25]. Available from: <https://www.path.org/media-center/path-and-mologic-advance-a-new-diagnostic-test-to-support-malaria-elimination/>
32. World Health Organization (WHO). List of WHO prequalified vector control products [Internet]. 2018 [cited 2018 Oct 6]. Available from: http://www.who.int/pq-vector-control/prequalified-lists/PQT_VC_17July2018.pdf?ua=1
33. Innovative Vector Control Consortium (IVCC). Annual report 2016-2017 [Internet]. 2017 [cited 2018 Oct 6]. Available from: <http://www.ivcc.com/about/governance/annual-reports>
34. James S, Collins FH, Welkhoff PA, Emerson C, Godfray HCJ, Gottlieb M, et al. Pathway to deployment of gene drive mosquitoes as a potential biocontrol tool for elimination of malaria in Sub-Saharan Africa: recommendations of a Scientific Working Group. *Am J Trop Med Hyg*. 2018 Jun 7;98(6_Suppl):1–49.
35. TB Alliance. Child-friendly medicines [Internet]. TB Alliance. 2017 [cited 2018 Jun 1]. Available from: <https://www.tballiance.org/child-friendly-medicines>
36. World Health Organization (WHO). Rapid communication: key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB) [Internet]. 2018 [cited 2018 Oct 6]. Report No.: WHO/CDS/TB/2018.18. Available from: http://www.who.int/tb/publications/2018/rapid_communications_MDR/en/
37. World Health Organization (WHO). Global tuberculosis report 2018 [Internet]. 2018 [cited 2018 Oct 6]. Available from: http://www.who.int/tb/publications/global_report/en/
38. World Health Organization (WHO). BCG vaccine [Internet]. [cited 2018 Jun 1]. Available from: <http://www.who.int/biologicals/areas/vaccines/bcg/en>
39. Van Der Meeren O, Hatherill M, Nduba V, Wilkinson RJ, Muyoyeta M, Van Brakel E, et al. Phase 2b controlled trial of M72/AS01 vaccine to prevent tuberculosis. *N Engl J Med* [Internet]. 2018 Sep 25 [cited 2018 Sep 26]; Available from: <http://www.nejm.org/doi/10.1056/NEJMoa1803484>
40. ClinicalTrials.gov. VAXCHORA pediatric study [Internet]. 2018 [cited 2018 Oct 7]. Available from: <https://clinicaltrials.gov/ct2/show/NCT03220737>
41. World Health Organization (WHO). WHO prequalified vaccines [Internet]. 2018 [cited 2018 Oct 7]. Available from: https://extranet.who.int/gavi/PQ_Web/Browse.aspx?nav=3

REFERENCES

42. World Health Organization (WHO). WHO prequalifies a thermostable rotavirus vaccine from India [Internet]. WHO. [cited 2018 Oct 7]. Available from: http://www.who.int/immunization/newsroom/news_WHO_prequalifies_thermostable_rotavirus_vaccine/en/
43. World Health Organization (WHO). Third Global Vaccine and Immunization Research Forum (GVIRF) [Internet]. WHO. 2018 [cited 2018 Oct 7]. Available from: http://www.who.int/immunization/research/forums_and_initiatives/gvirf/forum_2018/en/
44. Steele D, Kirkwood C, Ma L-F. Next generation rotavirus vaccines. WHO Product Development for Vaccines Advisory Committee (PDVAC) meeting 2018; 2018 Jun 26.
45. World Health Organization (WHO). WHO Product Development for Vaccines Advisory Committee (PDVAC) meeting 2018 [Internet]. WHO. 2018 [cited 2018 Oct 7]. Available from: http://www.who.int/immunization/research/meetings_workshops/pdvac_june18/en/
46. PATH. DefeatDD - drug development [Internet]. 2017 [cited 2018 Jun 1]. Available from: <https://www.defeatdd.org/solution/drug-development>
47. PATH. Reducing deadly diarrhea [Internet]. [cited 2017 Sep 21]. Available from: <http://www.path.org/projects/edd.php>
48. Centers for Disease Control and Prevention (CDC). American trypanosomiasis (also known as Chagas disease) [Internet]. 2016 [cited 2018 Jun 1]. Available from: <https://www.cdc.gov/parasites/chagas/index.html>
49. Gillespie PM, Beaumier CM, Strych U, Hayward T, Hotez PJ, Bottazzi ME. Status of vaccine research and development of vaccines for leishmaniasis. *Vaccine*. 2016 Jun 3;34(26):2992–5.
50. ClinicalTrials.gov. Topical liposomal amphotericin B gel treatment for cutaneous leishmaniasis [Internet]. 2017 [cited 2018 Jun 1]. Available from: <https://clinicaltrials.gov/ct2/show/NCT02656797>
51. FIND. Dx pipeline [Internet]. 2018 [cited 2018 Oct 7]. Available from: <https://www.finddx.org/dx-pipeline-status/>
52. Drugs for Neglected Diseases initiative (DNDi). Human African trypanosomiasis fact sheet [Internet]. 2016 [cited 2017 Jul 23]. Available from: https://www.dndi.org/wp-content/uploads/2017/08/Factsheet_2016_HAT.pdf
53. Keenan JD, Hotez PJ, Amza A, Stoller NE, Gaynor BD, Porco TC, et al. Elimination and eradication of neglected tropical diseases with mass drug administrations: a survey of experts. *PLoS Negl Trop Dis*. 2013 Dec 5;7(12):e2562.
54. TDR Disease Reference Group on Helminth Infections. Research priorities for helminth infections [Internet]. 2012 [cited 2017 Nov 18]. (WHO Technical Report Series on Helminth Infections). Report No.: 972. Available from: http://apps.who.int/iris/bitstream/10665/75922/1/WHO_TRS_972_eng.pdf
55. ClinicalTrials.gov. Study of safety and immune responses of the Sm14 vaccine in adults of endemic regions [Internet]. 2017 [cited 2018 Sep 26]. Available from: <https://clinicaltrials.gov/ct2/show/NCT03041766>
56. The Onchocerciasis Vaccine for Africa (TOVA) Initiative. The vaccine [Internet]. 2018 [cited 2018 Oct 7]. Available from: <https://www.riverblindnessvaccinetova.org/vaccine>
57. Pediatric Praziquantel Consortium. First patient dosed in Phase II clinical trial [Internet]. 2016 [cited 2018 Jun 1]. Available from: <http://www.pediatricpraziquantelconsortium.org/news-events/first-patient-dosed-phase-ii-clinical-trial>
58. PATH. Game-changing diagnostics for two neglected tropical diseases [Internet]. 2018 [cited 2018 Oct 7]. Available from: <https://www.path.org/articles/game-changing-diagnostics-two-neglected-tropical-diseases/>
59. Knopp S, Corstjens PLAM, Koukounari A, Cercamondi CI, Ame SM, Ali SM, et al. Sensitivity and specificity of a urine circulating anodic antigen test for the diagnosis of schistosoma haematobium in low endemic settings. *PLoS Negl Trop Dis*. 2015;9(5):e0003752.
60. World Health Organization Western Pacific Region (WPRO). Expert consultation to accelerate control of foodborne trematode infections, taeniasis and cysticercosis [Internet]. 2017. Available from: <http://iris.wpro.who.int/bitstream/handle/10665.1/13962/RS-2017-GE-35-KOR-eng.pdf>
61. Wong VK, Baker S, Pickard DJ, Parkhill J, Page AJ, Feasey NA, et al. Phylogeographical analysis of the dominant multidrug-resistant H58 clade of Salmonella Typhi identifies inter- and intracontinental transmission events. *Nat Genet N Y*. 2015 Jun;47(6):632–639B.
62. World Health Organization (WHO). Typbar TCV from Bharat Biotech, world's first typhoid conjugate vaccine prequalified by WHO [Internet]. 2018 [cited 2018 Sep 26]. Available from: <http://www.who.int/medicines/news/2017/Bharat-Biotech-TypbarTCV-WHO-PQ-Press-Release-Global-Final.pdf>
63. World Health Organization (WHO). Typhoid vaccines: WHO position paper – March 2018 [Internet]. 2018 Mar [cited

REFERENCES

- 2018 Sep 26]. Available from: <http://apps.who.int/iris/bitstream/handle/10665/272272/WER9313.pdf?ua=1>
64. Gavi, the Vaccine Alliance. New typhoid vaccine to receive Gavi support [Internet]. 2018 [cited 2018 Sep 26]. Available from: <https://www.gavi.org/library/news/statements/2018/new-typhoid-vaccine-to-receive-gavi-support/>
 65. Martin LB, Simon R, MacLennan CA, Tennant SM, Sahastrabuddhe S, Khan MI. Status of paratyphoid fever vaccine research and development. *Vaccine*. 2016;34(26):2900–2.
 66. Shuan Ju Teh C, Heng Chua K, Lin Thong K. Paratyphoid fever: splicing the global analyses. *Int J Med Sci*. 2014;11(7):732–41.
 67. Tennant SM, MacLennan CA, Simon R, Martin LB, Khan MI. Nontyphoidal salmonella disease: current status of vaccine research and development. *Vaccine*. 2016 Jun 3;34(26):2907–10.
 68. World Health Organization (WHO). Dengue and severe dengue fact sheet [Internet]. 2017 [cited 2017 Nov 10]. Available from: <http://www.who.int/mediacentre/factsheets/fs117/en/>
 69. Hilgenfeld R, Vasudevan SG. Dengue and Zika: control and antiviral treatment strategies [Internet]. Springer Singapore; 2018. (Advances in Experimental Medicine and Biology; vol. 1062). Available from: <https://www.springer.com/gp/book/9789811087264>
 70. Hunsperger EA, Yoksan S, Buchy P, Nguyen VC, Sekaran SD, Enria DA, et al. Evaluation of commercially available diagnostic tests for the detection of dengue virus NS1 antigen and anti-dengue virus IgM antibody. *PLoS Negl Trop Dis*. 2014 Oct 16;8(10):e3171.
 71. Waggoner JJ, Abeynayake J, Sahoo MK, Gresh L, Tellez Y, Gonzalez K, et al. Comparison of the FDA-approved CDC DENV-1-4 real-time reverse transcription-PCR with a laboratory-developed assay for dengue virus detection and serotyping. *J Clin Microbiol*. 2013 Oct;51(10):3418–20.
 72. Murtagh MM. Flavivirus diagnostic landscape - focusing on dengue and Zika flavivirus diagnostics [Internet]. Workshop on new and innovative approaches to laboratory diagnosis of Zika, dengue and other arboviruses; 2017 May 2 [cited 2018 Sep 26]; Veyrier-du-Lac, France. Available from: <http://www.controldengue.org/wp-content/uploads/2017/06/maurine-murtagh.pdf>
 73. Dauner AL, Mitra I, Gilliland T, Seales S, Pal S, Yang S-C, et al. Development of a pan-serotype reverse transcription loop-mediated isothermal amplification assay for the detection of dengue virus. *Diagn Microbiol Infect Dis*. 2015 Sep;83(1):30–6.
 74. World Health Organization (WHO). Overview of product classes and prototype/products under Vector Control Advisory Group (VCAG) review for assessment of public health value [Internet]. 2018. Available from: <http://apps.who.int/iris/bitstream/handle/10665/274451/WHO-CDS-VCAG-2018.03-eng.pdf?ua=1>
 75. World Health Organization (WHO). Meningococcal meningitis fact sheet [Internet]. World Health Organization. 2018 [cited 2018 Jul 10]. Available from: <http://www.who.int/news-room/fact-sheets/detail/meningococcal-meningitis>
 76. World Health Organization (WHO). Pneumococcal vaccines WHO position paper 2012 [Internet]. 2012 Jun [cited 2017 Jul 23]. Available from: <http://www.who.int/wer/2012/wer8714.pdf?ua=1>
 77. Alderson MR. Status of research and development of pediatric vaccines for *Streptococcus pneumoniae*. *Vaccine*. 2016 Jun 3;34(26):2959–61.
 78. Pichichero ME. Pneumococcal whole-cell and protein-based vaccines: changing the paradigm. *Expert Rev Vaccines*. 2017 Dec 2;16(12):1181–90.
 79. UNICEF Supply Division. Meningitis vaccine market supply update [Internet]. UNICEF; 2015 [cited 2017 Nov 18]. Available from: https://www.unicef.org/supply/index_vaccines.html
 80. ClinicalTrials.gov. Clinical study of meningococcal ACYWX conjugate vaccine, in 12-16 month olds [Internet]. 2017 [cited 2018 Jun 1]. Available from: <https://clinicaltrials.gov/ct2/show/NCT03295318>
 81. World Health Organization (WHO). Hepatitis C fact sheet [Internet]. World Health Organisation. 2018 [cited 2018 Jul 11]. Available from: <http://www.who.int/news-room/fact-sheets/detail/hepatitis-c>
 82. Messina J, Humphreys I, Flaxman A, Brown A, Cooke G, Pybus O, et al. Global distribution and prevalence of hepatitis C virus genotypes. *Hepatology*. 2015 Jan;61(1):77–87.
 83. World Health Organization (WHO). Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection [Internet]. 2018 [cited 2018 Oct 7]. Available from: <http://www.who.int/hepatitis/publications/hepatitis-c-guidelines-2018/en/>

REFERENCES

84. World Health Organization (WHO). Progress report on access to hepatitis C treatment [Internet]. 2018 Mar [cited 2018 Oct 7]. Report No.: WHO/CDS/HIV/18.4. Available from: <http://www.who.int/hepatitis/publications/hep-c-access-report-2018/en/>
85. World Health Organization (WHO). Public reports of WHO prequalified IVDs [Internet]. 2018 [cited 2018 Oct 7]. Available from: http://www.who.int/diagnostics_laboratory/evaluations/pq-list/hcv/public_report/en/
86. Burnet Institute. HCV vaccine [Internet]. 2017 [cited 2018 Jun 1]. Available from: https://www.burnet.edu.au/projects/14_hcv_vaccine
87. World Health Organization (WHO). Guidelines for the diagnosis, treatment and prevention of leprosy - Executive summary [Internet]. 2018 [cited 2018 Oct 7]. Available from: http://www.searo.who.int/entity/global_leprosy_programme/approved-guidelines-leprosy-executives-summary.pdf?ua=1
88. World Health Organization (WHO). Global leprosy strategy 2016-2020 [Internet]. WHO. 2016 [cited 2018 Jun 20]. Available from: <http://www.who.int/lep/resources/9789290225096/en/>
89. Hotez P, Pecoul B. "Manifesto" for advancing the control and elimination of neglected tropical diseases. *PLoS Negl Trop Dis*. 2010;4(5):e718.
90. Gelber R, Andries K, Paredes RMD, Andaya CES, Burgos J. The diarylquinoline R207910 is bactericidal against *Mycobacterium leprae* in mice at low dose and administered intermittently. *Antimicrob Agents Chemother*. 2009 Sep;53(9):3989–3991.
91. Bahmanyar E, Smith WC, Brennan P, Cummings R, Duthie M, Richardus JH, et al. Leprosy diagnostic test development as a prerequisite towards elimination: requirements from the user's perspective. *PLoS Negl Trop Dis*. 2016;10(2):e0004331.
92. Infectious Disease Research Institute (IDRI). Our products [Internet]. 2017 [cited 2018 Jun 1]. Available from: <http://www.idri.org/products/pipeline/>
93. Williamson PR, Jarvis JN, Panackal AA, Fisher MC, Molloy SF, Loyse A, et al. Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy. *Nat Rev Neurol*. 2017 Jan;13(1):13–24.
94. Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. *Lancet Infect Dis* [Internet]. 2017 May 5 [cited 2017 Jun 22];0(0). Available from: [http://www.thelancet.com/journals/laninf/article/PIIS1473-3099\(17\)30243-8/abstract](http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(17)30243-8/abstract)
95. Park B, Wannemuehler K, Marston B, Govender N, Chiller T. Estimation of the global burden of cryptococcal meningitis among persons living with HIV/AIDS. *AIDS*. 2009;23(4):525–30.
96. Centers for Disease Control and Prevention (CDC). Preventing deaths from cryptococcal meningitis [Internet]. 2017 [cited 2018 Jun 1]. Available from: <https://www.cdc.gov/fungal/global/cryptococcal-meningitis.html>
97. Sloan D, Parris V. Cryptococcal meningitis: epidemiology and therapeutic options. *Clin Epidemiol*. 2014 May;13(6):169–82.
98. National Institutes of Health (NIH). Development of the novel antifungal VT-1129 for cryptococcal meningitis [Internet]. National Center for Advancing Translational Sciences. 2015 [cited 2018 Oct 7]. Available from: <https://ncats.nih.gov/trnd/projects/complete/antifungal-vt1129-cryptococcal-meningitis>
99. Loyse A, Thangaraj H, Easterbrook P, Ford N, Roy M, Chiller T, et al. Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries. *Lancet Infect Dis*. 2013 Jul;13(7):629–37.
100. Torgerson PR, Hagan JE, Costa F, Calcagno J, Kane M, Martinez-Silveira MS, et al. Global burden of leptospirosis: estimated in terms of Disability Adjusted Life Years. *PLoS Negl Trop Dis* [Internet]. 2015 Oct 2 [cited 2017 Apr 21];9(10). Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4591975/>
101. Dittrich S, Boutthasavong L, Keokhamhoung D, Phuklia W, Craig SB, Tulsiani SM, et al. A prospective hospital study to evaluate the diagnostic accuracy of rapid diagnostic tests for the early detection of leptospirosis in Laos. *Am J Trop Med Hyg*. 2018 Apr;98(4):1056.
102. World Health Organization (WHO). Buruli ulcer, number of new reported cases. Data by country [Internet]. WHO Global Health Observatory. 2018 [cited 2018 Nov 14]. Available from: <http://apps.who.int/gho/data/node.main.A1631>
103. Sakyi SA, Aboagye SY, Darko Otchere I, Yeboah-Manu D. Clinical and laboratory diagnosis of buruli ulcer disease: a systematic review. *Can J Infect Dis Med Microbiol J Can Mal Infect Microbiol Médicale* [Internet]. 2016 [cited 2017 Nov 18];2016. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4931084/>

REFERENCES

104. Yotsu RR, Richardson M, Ishii N. Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease). *Cochrane Database Syst Rev* [Internet]. 2018 [cited 2018 Oct 15];(8). Available from: <https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012118.pub2/abstract>
105. Owusu E, Newman MJ, Kotey NK, Akumwena A, Bannerman E. Susceptibility profiles of Mycobacterium ulcerans isolates to streptomycin and rifampicin in two districts of the eastern region of Ghana. *Int J Microbiol*. 2016;2016:8304524.
106. Roupie V, Pidot SJ, Einarsdottir T, Poel CVD, Jurion F, Stinear TP, et al. Analysis of the vaccine potential of plasmid DNA encoding nine mycolactone polyketide synthase domains in mycobacterium ulcerans infected mice. *PLoS Negl Trop Dis*. 2014 Jan 2;8(1):e2604.
107. World Health Organization (WHO). Trachoma fact sheet [Internet]. World Health Organization. 2018 [cited 2018 Jun 12]. Available from: <http://www.who.int/news-room/fact-sheets/detail/trachoma>
108. Inic-Kanada A, Stojanovic M, Schlacher S, Stein E, Belij-Rammerstorfer S, Marinkovic E, et al. Delivery of a chlamydial adhesin N-PmpC subunit vaccine to the ocular mucosa using particulate carriers. *PLoS One San Franc*. 2015 Dec;10(12):e0144380.
109. Goodhew EB, Priest JW, Moss DM, Zhong G, Munoz B, Mkocha H, et al. CT694 and pgp3 as serological tools for monitoring trachoma programs. *PLoS Negl Trop Dis*. 2012 Jan 11;6(11):e1873.
110. Migchelsen SJ, Martin DL, Southisombath K, Turyaguma P, Heggen A, Rubangakene PP, et al. Defining seropositivity thresholds for use in trachoma elimination studies. *PLoS Negl Trop Dis*. 2017 Jan 18;11(1):e0005230.
111. ClinicalTrials.gov. A controlled study to evaluate the safety and immunogenicity of StreptAnova in healthy adults [Internet]. 2017 [cited 2018 Sep 27]. Available from: <https://clinicaltrials.gov/ct2/show/NCT02564237>
112. Oyston P, Robinson K. The current challenges for vaccine development. *J Med Microbiol*. 2012 Jul;61(Pt 7):889–94.
113. National Institute of Allergy and Infectious Diseases (NIAID). NIAID role in vaccine adjuvant research [Internet]. [cited 2018 Oct 10]. Available from: <https://www.niaid.nih.gov/research/vaccine-adjuvant-research-niaid-role>
114. Grand Challenges. Microcubes as vaccines for the developing world [Internet]. 2009 [cited 2018 Oct 11]. Available from: <https://gcgh.grandchallenges.org/grant/microcubes-vaccines-developing-world>
115. Trafton A. New capsule achieves long-term drug delivery [Internet]. MIT News. 2018 [cited 2018 Oct 11]. Available from: <http://news.mit.edu/2016/new-capsule-long-term-drug-delivery-malaria-1116>
116. Global Good [Internet]. Intellectual Ventures. [cited 2018 Nov 1]. Available from: <http://www.intellectualventures.com/globalgood>
117. Lensless microscope for diagnostics [Internet]. Global Grand Challenges. 2009 [cited 2018 Oct 10]. Available from: <https://gcgh.grandchallenges.org/grant/lensless-microscope-diagnostics>
118. Unitaid. New testing technologies save children's lives while fighting antimicrobial resistance [Internet]. Unitaid. 2018 [cited 2018 Oct 10]. Available from: <https://unitaid.org/news-blog/new-testing-technologies-save-childrens-lives-fighting-antimicrobial-resistance/>
119. Esvelt KM. Gene drives [Internet]. 2018 [cited 2018 Oct 10]. Available from: <http://www.sculptingevolution.org/genedrives>
120. Kupferschmidt K, Science magazine. After 40 years, the most important weapon against mosquitoes may be failing [Internet]. Science. 2016 [cited 2018 Oct 10]. Available from: <https://www.sciencemag.org/news/2016/10/after-40-years-most-important-weapon-against-mosquitoes-may-be-failing>
121. Hapairai LK, Mysore K, Chen Y, Harper EI, Scheel MP, Lesnik AM, et al. Lure-and-kill yeast interfering RNA larvicides targeting neural genes in the human disease vector mosquito *Aedes aegypti*. *Sci Rep*. 2017 Oct 16;7(1):13223.
122. The Bill and Melinda Gates Foundation. The Bill & Melinda Gates Medical Research Institute [Internet]. The Bill and Melinda Gates Foundation. 2017 [cited 2018 Nov 5]. Available from: <https://www.gatesfoundation.org/~media/gfo/media-center/gates-mri-overview-26may2017.pdf?la=en>